Objective To observe the effects of dapagliflozin on bone metabolism in patients with type 2 diabetes mellitus(T2DM) and provide guidance for the clinical dynamic monitoring of drug use safety.

Methods A total of 38 T2DM patients taking dagaglizin were selected as dagaglizin group, and 42 T2DM patients using other hypoglycemic programs were selected as non-daglizin group.The glucose and lipid metabolism indexes and bone metabolism indexes in two groups were measured, and the differences between wo groups were compared.Correlation analysis and multiple linear regression analysis were used to predict the related factors affecting bone metabolism indexes of the patients.

Results The levels of triglyceride(TG), 1, 25-dihydroxyvitamin D(1, 25(OH)₂D) and 1-hydroxylase(CYP27B1) in the dapagliflozin group were significantly lower than those in non-dapagliflozin group(P < 0.01).The parathyroid hormone(PTH) and type Ⅰ collagen cross-linked C-terminal peptide(S-CTX) in the dapagliflozin group were significantly higher than those in non-dapagliflozin group(P < 0.05).The results of correlation analysis showed that the S-CTX was negatively correlated with TG(r=-0.318) and sodium(r=-0.455), and positively correlated with PTH(r=0.319).There was no correlation between P1NP and other indexes.The results of multiple linear regression analysis showed that the low sodium, low TG, high PTH and taking dapagliflozin were the main risk factors of S-CTX.

Conclusions Daglipzin enhances bone resorption in T2DM patients, possibly by reducing TG, 1, 25(OH)₂D and increasing PTH.